Objective To explore the effects of Qingfei Paidu Decoction（QFPDD

清肺排毒汤） in the treatment of mild/moderate cases of coronavirus disease 2019（COVID-19）. Methods A total of 295 mild/moderate cases of COVID-19 admitted to five Wuhan mobile cabin hospitals from February 5 th to March 10 th

2020 were included

and divided into QFPDD group（199 cases） and combination group（96 cases） according to the treatment therapies. QFPDD

one dose daily

was orally administered in QFPDD group

while western medicine and Chinese patent medicine in addition to QFPDD were given in combination group. Rate of disease progression into severe/critically severe cases

average length of hospitalization

improvement of clinical symptoms including fever

cough

expectoration

sore throat

fatigue

headache

diarrhea

suffocation and CT imaging were assessed. Results No cases in both groups were found to progress into severe or critically severe disease. The median hospitalization length and nucleic acid negative conversion time were 9 days（7-12 days） and 5 days（3-9 days） in the QFPDD group

while those in the combination group were 16 days（11-22 days） and 10 days（7-14 days）

with significantly differences between groups（P<0.05）. The disappearance time of expectoration in the QFPDD group was significantly shorter than that in the combination group（P<0.05）

while there were no significant differences in the disappearance time of other main symptoms between groups（P>0.05）. The chest CT absorption rate in the QFPDD group was 95.0%（153/161）

and that of the combination group was 91.2%（83/91）; the difference between groups was statistically significant（P<0.05）. Conclusion QFPDD alone can promote negative conversion of nucleic acid

improve chest CT and expectoration symptoms

and shorten the length of hospitalization for treating mild/moderate cases of COVID-19

having certain advantages over drug combination treatment.